Moderna vaccines better protect long-term care home residents
McMaster UniversityModerna vaccines are better than Pfizer in protecting residents of long-term care (LTC) homes from COVID-19 Omicron infections, say McMaster University researchers.
Moderna vaccines are better than Pfizer in protecting residents of long-term care (LTC) homes from COVID-19 Omicron infections, say McMaster University researchers.
Two studies presented today at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo reveal how SARS-CoV-2 antibody levels vary among recipients of COVID-19 vaccines and naturally infected individuals. These findings add to a growing body of knowledge that is essential for guiding public health initiatives, and that might one day enable clinicians to assess individuals’ immunity to SARS-CoV-2.
In a new article published in the Journal for ImmunoTherapy of Cancer, Moffitt Cancer Center researchers demonstrate how mathematical modeling can be used to analyze the impact of different cancer treatments on tumor and immune cell dynamics and help predict outcomes to therapy and personalize cancer treatment.
七月是肉瘤宣传月,旨在引起人们对这种疾病的关注,肉瘤是一系列起源于身体骨骼或软组织的癌症。肉瘤有70多种类型,包括骨癌。骨癌的治疗方法包括针对癌症的手术、化疗、放疗或质子束治疗。
مدينة روتشستر، ولاية مينيسوتا: يعد تموز/يوليو هو شهر التوعية بالساركوما وللفت الانتباه لمجموعة من السرطانات التي تبدأ في العظام أو الأنسجة الرخوة في الجسم. هناك أكثر من 70 نوعاً من الساركوما، منها سرطان العظام. وتشمل طرق علاج سرطان العظام الجراحة والعلاج الكيميائي والعلاج الإشعاعي والعلاج الإشعاعي بحزم البروتونات الذي يستهدف الخلايا السرطانية.
The premier global laboratory medicine exposition to be held at the McCormick Place Convention Center in Chicago, July 24-28, 2022.
Julio es el mes para concienciar sobre el sarcoma y llamar la atención sobre aquel grupo de cánceres que empiezan en los huesos o en los tejidos blandos del cuerpo. Hay más de 70 tipos de sarcoma, entre ellos, el cáncer de hueso.
Julho é o Mês da Conscientização do Sarcoma, chamando a atenção para um grupo de cânceres que começa nos ossos ou nos tecidos moles do corpo. Existem mais de 70 tipos de sarcoma, incluindo o câncer ósseo.
Cytovale®, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, will reveal its 510(k) pending Cytovale system and 10-minute IntelliSep® sepsis risk stratification test at the American Association for Clinical Chemistry (AACC) annual meeting, where new data featuring the test will also be shared. The instrument can be seen in the Cytovale booth, no. 5045, in the exhibit hall during Clinical Lab Expo hours. The IntelliSep test was recently named an AACC Disruptive Technology Award Semifinalist and is also being featured in the Disruptive Tech area of the exhibit hall during the meeting.
Researchers at Mayo Clinic's Center for Individualized Medicine have discovered key human genomic signatures that could help explain why COVID-19 is severe in some people and mild in others. After analyzing volumes of diverse worldwide DNA sequence data, the scientists identified mutations in two human proteins that might sway the course of SARS-CoV-2 — the virus responsible for COVID-19.
The Omicron variant of the SARS-CoV-2 virus was first detected in South Africa in November 2021. The high level of infectiousness of the virus and its ability to quickly spawn additional variants has also been observed in Germany: Since January 2022 the Omicron variant BA.1 has dominated here, followed in subsequent months by the variant BA.2.
For patients with lymphoma, multiple myeloma, or certain types of leukemia, treatment with chimeric antigen receptor T cells (CAR T cells) is sometimes the last chance of overcoming the cancer.
For a glimpse into the future of SARS-CoV-2 immunity, scientists at La Jolla Institute for Immunology (LJI) are investigating how the immune system builds its defenses against common cold coronaviruses (CCCs).
Our immune system is essential for our survival, as our bodies are constantly being exposed to bacteria, viruses, parasites, and other pathogens.
Patients infected with SARS-CoV-2 develop protective immune responses, mediated by virus-specific T cells and antibodies, shortly after the infection.
Cancer cells produce small amounts of their own form of collagen, creating a unique extracellular matrix that affects the tumor microbiome and protects against immune responses, according to a new study by researchers at The University of Texas MD Anderson Cancer Center. This abnormal collagen structure is fundamentally different from normal collagen made in the human body, providing a highly specific target for therapeutic strategies.
Protection against severe COVID-19 by two doses of Pfizer-BioNTech and AstraZeneca COVID-19 vaccines remained high up to six months after second doses, finds new research which analysed NHS health record data on over seven million adults. Reassuringly, the University of Bristol-led study published in The BMJ today [July 20], found protection in older adults aged over 65 years, and in clinically vulnerable adults.
Paramyxoviruses have the potential to trigger a devastating pandemic. This family of viruses includes measles, Nipah virus, mumps, Newcastle disease and canine distemper. An international team of collaborators has published the first-ever look at a key stage in the life cycles of measles and Nipah viruses. It reveals how future therapies might stop these viruses in their tracks.
Tufts University School of Medicine immunologist Pilar Alcaide explains what autoimmune diseases are, what causes them, who gets them the most, and what can be done about them.
Those widely available COVID-19 vaccinations keeping the majority of the population free from serious illness will not be enough to stop the spread of the virus and its variants, new University of Virginia collaborative research indicates.
Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substantially within 3 months, according to new clinical trial data.
In a new study, researchers show how a critical Lassa virus protein, called polymerase, drives infection by harnessing a cellular protein in human hosts. Their work suggests future therapies could target this interaction to treat patients.
As new Omicron subvariants of COVID-19 continue to sweep across the United States, researchers at the University of Missouri have identified specific mutations within the virus’ spike protein that help Omicron subvariants evade existing antibodies humans have from either vaccines or previous COVID-19 infections.
Adding immunotherapy to standard anti-rejection medication could change the lives of thousands of kidney transplant patients with incurable cancer, as new research shows it can reduce this risk of organ rejection and eliminate cancer in a quarter of patients.
A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of chemotherapy alone. Results of the research were presented by Stephen Ansell, M.D., Ph.D., at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago and were published today in the New England Journal of Medicine.
Of all the fungi that live in the human body, the most infamous is probably the yeast Candida.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include new targets involved in protecting DNA replication forks and preventing inflammatory responses, a new treatment option for elderly patients with late-stage acute myeloid leukemia, insights into the breast cancer tumor microenvironment, biomarkers of response to targeted and immune therapies, a novel cellular therapy option for osteosarcoma and a new target for inducing ferroptosis in cancer cells.
As part of UChicago Medicine's community engagement efforts, the public is invited to provide input to inform the services and offerings at what will be the state’s only freestanding comprehensive cancer center.
People with systemic lupus erythematosus, or SLE, who received a “booster” dose of SARS-CoV-2 vaccine after full vaccination are roughly half as likely to have a subsequent “breakthrough” COVID-19 infection, a new study shows.
When infants breastfeed, they receive an immune boost that helps them fight off infectious diseases, according to recent research from Binghamton University, State University of New York.
Most patients in the study mounted immune responses after a booster dose, and no patient with antibody responses died from COVID-19.
Using UT Southwestern’s Cryo-Electron Microscopy Facility, researchers for the first time have captured images of an autoantibody bound to a nerve cell surface receptor, revealing the physical mechanism behind a neurological autoimmune disease. The findings, published in Cell, could lead to new ways to diagnose and treat autoimmune conditions, the study authors said.
Human immunodeficiency virus 1, more commonly known as HIV-1, is known for its uncanny ability to evade the immune system.
Researchers at the University of Southampton have gained unprecedented new insight into the key properties of an antibody needed to fight off cancer.
In a new article published in Cancer Research Communications, Moffitt Cancer Center researchers describe the signaling pathways that regulate YAP1 and how the protein contributes to angiogenesis under normal and low oxygen conditions.
UC San Diego researchers say they may have found the reason why multiple human clinical trials of staphylococcus vaccines have failed: the bacteria knows us too well.
A new type of vaccine provides protection against a variety of SARS-like betacoronaviruses, including SARS-CoV-2 variants, in mice and monkeys, according to a study led by researchers in the laboratory of Caltech's Pamela Bjorkman, the David Baltimore Professor of Biology and Bioengineering.
Users of fourth-generation nicotine-salt-containing devices, such as Juul and disposable devices, display a unique mix of cellular biomarkers indicative of immune suppression.
Could the SARS-CoV-2 vaccine reawaken previous antibody responses and point the way to a universal coronavirus vaccine? A new analysis of the antibody response to a COVID-19 vaccine suggests the immune system’s history with other coronaviruses, including those behind the common cold, shapes the patient’s response, according to a recently published study published in Cell Reports.
A COVID CommUNITY – South Asian study, published in the Canadian Medical Association Journal (CMAJ) Open has found that South Asian communities living in the Greater Toronto Area (GTA) suffered disproportionately from COVID-19 in the first year of the pandemic.
COVID-19 vaccines greatly reduced the number of cases of severe COVID-19 disease for everyone regardless of their body size, according to a new study published in The Lancet Diabetes & Endocrinology. Vaccine effectiveness was similar for those with a higher BMI and of a healthy weight, but slightly lower in the underweight group, who were also the least likely to have been vaccinated.
A new universal flu vaccine constructed with key parts of the influenza virus offers broad cross protection against different strains and subtypes of influenza A viruses in young and aged populations, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.
The experts agree — the pandemic is not over. Infections are ticking up again, fueled by the new variants our immune systems are ill prepared for.
Despite significant and stunning advances in vaccine technology, the COVID-19 global pandemic is not over.
Researchers are expanding their understanding of unique immune “memory” cells equipped to remember malicious invaders. They developed an atlas that describes tissue-resident memory cells in diverse settings, boosting prospects for new immune defense strategies at vulnerable infection sites.
A major clinical trial, led by experts at the University of Nottingham working in partnership with several Universities and NHS hospitals, has found that by interrupting the treatment of vulnerable people on long-term immune supressing medicines for two weeks after a COVID-19 booster vaccination, their antibody response to the jab is doubled.
A new study has found that a highly antibiotic-resistant strain of the superbug MRSA – methicillin resistant Staphylococcus aureus – has emerged in livestock in the last 50 years, probably due to widespread antibiotic use in pig farming.